IGC Pharma, Inc. (India Globalization Capital, Inc.) — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2021, compared with fiscal 2020. Although the request metadata identifies “2020 Q4,” this filing is an annual report for fiscal 2021, not a standalone quarterly report. Financial amounts below are in U.S. dollars; tables are in thousands unless otherwise noted.
Business context and reporting period
IGC operates Life Sciences and Infrastructure segments. Life Sciences combines cannabinoid drug research and development with wellness and lifestyle products; Infrastructure includes construction work, equipment rental, and commodity trading, primarily in India and Hong Kong. The company is shifting its focus toward Life Sciences. Fiscal 2021 Life Sciences revenue was driven primarily by hand sanitizer sales during the COVID-19 pandemic, while Infrastructure activity was sharply curtailed.
The lead pharmaceutical candidate, IGC-AD1, is an oral THC-based formulation under investigation for Alzheimer’s-related symptoms. The company also developed the Holief, Herbo, and Sunday Seltzer brands. It held three issued cannabinoid-related patents and had additional applications pending. The filing’s financial statements received an unqualified audit opinion.
Financial performance and position
| Metric | FY2021 | FY2020 | Change / context |
|---|---|---|---|
| Revenue | $898 | $4,072 | Down 78% |
| Gross profit | $113 | $115 | Nearly unchanged despite much lower sales |
| Gross margin | 12.6% | 2.8% | Improved, but on substantially lower revenue |
| SG&A | $7,908 | $5,968 | Up 33% |
| Research and development | $929 | $1,011 | Down 8%; management expects spending to rise as IGC-AD1 trials progress |
| Operating loss | $(8,724) | $(6,864) | Loss widened |
| Net loss | $(8,811) | $(7,315) | Loss widened; basic and diluted loss per share was $(0.21) versus $(0.19) |
| Cash used in operating activities | $(10,800) | $(8,677) | Operating cash outflow increased |
| Cash and cash equivalents at year-end | $14,548 | $7,258 | Up $7,290, principally following equity issuance |
| Working capital | $21,149 | $15,811 | Up 34% |
| Total liabilities | $3,064 | $2,447 | Includes $580 of loans at FY2021 year-end |
Revenue mix changed substantially: Life Sciences generated $723 (80% of total revenue), versus $411 in FY2020; Infrastructure generated $175 (20%), versus $3,661. Infrastructure commodity resale revenue fell from $3,553 to zero. The filing attributes the deterioration chiefly to pandemic restrictions and reduced activity in India and Hong Kong. Most FY2021 revenue came from hand sanitizers.
Liquidity was supported by approximately $14,158 of net proceeds from an at-the-market (ATM) equity offering. The company sold approximately 6.5 million shares through the ATM in FY2021; its sales agreement authorized up to $75 million in aggregate offerings. Financing cash flow was $14,688, while investing activities provided $3,387, including approximately $5,081 of proceeds from marketable securities. Marketable securities were zero at March 31, 2021. The company reported no material long-term debt, although it had short- and long-term loans totaling $580, including PPP and Economic Injury Disaster loans.
Material changes, outlook, risks, and unusual items
- Costs and operating items: SG&A included approximately $225 of one-time settlement expense, a $200 legal-fee provision, and $307 of inventory-related adjustments. The company recorded a $169 impairment on its Evolve investment; it had recorded $782 of investment impairment in FY2020.
- Inventory and vendor exposure: Inventory rose to $5,478 from $4,245. A vendor holding $1,740 of company inventory reported a theft at its facility; IGC reclassified the associated amount to deposits and advances. The filing does not establish that the inventory or related receivable will be recovered. Separately, approximately $307 of inventory was written off.
- Clinical development: The FDA allowed a 12-subject Phase 1 trial of IGC-AD1 to proceed after removing a full clinical hold in July 2020. After year-end, the company announced completion of Cohorts 1 and 2; the independent safety committee recommended proceeding to Cohort 3. The trial was anticipated to conclude in FY2022’s second quarter. Phase 2 remains contingent on trial results, funding, and regulatory requirements; no efficacy or approval guidance was provided.
- Management outlook: Management expected Infrastructure revenue to remain reduced in FY2022 while COVID-19 affected operating regions, and cited limited visibility and volatility in both segments. It anticipated higher R&D costs as IGC-AD1 advances. Management stated that available cash, cash equivalents, marketable securities, and liquidity arrangements were expected to cover needs for the next 12 months, while also saying it would continue to raise capital when able.
- Financing and dilution: The ATM provides potential additional funding but may dilute shareholders. Management described a broad range of possible uses of proceeds, including operations, clinical trials, debt repayment, share repurchases, and investments.
- Contingencies: The company accrued $200 for shareholder class-action litigation. After year-end, the parties reached a preliminary settlement agreement; it remained subject to formal documentation and court approval. Management expected most of the settlement to be covered by insurance, but gave no assurance of final approval or coverage.
- Other material risks: IGC has a history of operating losses and substantial operating cash outflows; relies on financing; faces clinical-trial, FDA, cannabinoid regulation, manufacturing, market-acceptance, and COVID-19 risks; and noted that cannabis-related perceptions may make raising capital more difficult. The company also stated that its Washington processing facility had not completed commissioning and that GMP certification was not assured.
Most important facts for investors to verify
- Whether the shareholder settlement received court approval, its final cost, and the amount actually covered by insurance.
- IGC-AD1’s Phase 1 completion, safety and pharmacokinetic results, and whether later-stage trials are funded and authorized.
- Current cash, operating cash burn, financing needs, and shares issued or remaining available under the ATM.
- The status and recoverability of the $1,740 associated with the vendor theft, the related inventory, and other inventory balances and write-offs.
- Whether the Washington facility was commissioned and obtained required GMP certification, and whether hemp-derived product sales comply with applicable regulations.
- The company’s progress in replacing pandemic-related sanitizer revenue with recurring sales from its branded products and Infrastructure operations.